RecruitingNot ApplicableNCT06503510

Role of Interleukin-13 Pathways on Pain and Itch Sensitivity

The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers

Sponsor

Aalborg University

Enrollment

20 participants

Start Date

Jan 6, 2025

Study Type

INTERVENTIONAL

Conditions

Itch

Summary

Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Cowhage, Histamine, and others for people with itch. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHistamine

A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

OTHERCowhage

Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.

OTHERbovine adrenal medulla (BAM8-22)

A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.